Showing results (1-10 of 7) with videos related to
Sort By:
Pageof 1
Pharmacoeconomics - Open|April 22, 2025
Indirect Treatment Comparisons in EUnetHTA Relative Effectiveness Assessments: Learnings and Recommendations for the Implementation of EU Joint Clinical AssessmentsSophie van Beekhuizen, Menglu Che, Loraine Monfort, et al.Oncology and Therapy|May 17, 2025
A Cost-Effectiveness Analysis for Avelumab as a First-Line Maintenance Treatment of Advanced Urothelial Carcinoma in the NetherlandsDavid Smalbrugge, Tim Walsteijn, Jeantine de Feijter, et al.Journal of Comparative Effectiveness Research|September 12, 2022
Novel and existing flexible survival methods for network meta-analysesBart Heeg, Andrea Garcia, Sophie van Beekhuizen, et al.European Urology Oncology|October 31, 2025
Systematic Review of the Definition of Cure and of Curative-intent Treatments in Early Bladder CancerFélix Guerrero-Ramos, Carsten Schwenke, Álvaro Pinto, et al.Leukemia & Lymphoma|November 6, 2019
A matching-adjusted indirect treatment comparison (MAIC) of daratumumab-bortezomib-melphalan-prednisone (D-VMP) versus lenalidomide-dexamethasone continuous (Rd continuous), lenalidomide-dexamethasone 18 months (Rd 18), and melphalan-prednisone-thalidomide (MPT)Meletios A Dimopoulos, Michele Cavo, Maria-Victoria Mateos, et al.Advances in Therapy|March 5, 2022
Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysisThierry Facon, Jesús San-Miguel, Meletios A Dimopoulos, et al.Advances in Therapy|July 3, 2024
Feasibility of Indirect Treatment Comparisons Between Niraparib Plus Abiraterone Acetate and Other First-Line Poly ADP-Ribose Polymerase Inhibitor Treatment Regimens for Patients with BRCA1/2 Mutation-Positive Metastatic Castration-Resistant Prostate CancerMaria De Santis, Sara Martínez Breijo, Paul Robinson, et al.Pageof 1